Founders Capital Management (Texas)’s Lineage Cell Therapeutics LCTX Stock Holding History

Founders Capital Management (Texas)’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$15.3K	Hold	16,000	–	–	0.01%	67
2026 Q2	$21K	Hold	16,000	–	–	0.01%	264
2026 Q1	$25.3K	Buy	16,000 +4,000	+33%	+$6.75K	0.01%	220
2025 Q4	$20K	Hold	12,000	–	–	0.01%	243
2025 Q3	$20.3K	Hold	12,000	–	–	0.01%	238
2025 Q2	$10.9K	Hold	12,000	–	–	0.01%	278
2025 Q1	$5.42K	Buy	+12,000	New	+$7.04K	﹤0.01%	305
2024 Q4	–	Sell	-15,000	Closed	-$13.6K	–	381
2024 Q3	$13.6K	Buy	15,000 +7,000	+88%	+$6.49K	0.01%	268
2024 Q2	$7.98K	Hold	8,000	–	–	0.01%	296
2024 Q1	$11.8K	Hold	8,000	–	–	0.01%	275
2023 Q4	$8.72K	Hold	8,000	–	–	0.01%	297
2023 Q3	$9.44K	Hold	8,000	–	–	0.01%	298
2023 Q2	$11.3K	Hold	8,000	–	–	0.01%	297
2023 Q1	$12K	Hold	8,000	–	–	0.01%	298
2022 Q4	$9K	Hold	8,000	–	–	0.01%	308
2022 Q3	$9K	Hold	8,000	–	–	0.01%	305
2022 Q2	$13K	Hold	8,000	–	–	0.01%	282
2022 Q1	$20K	Hold	8,000	–	–	0.01%	211
2021 Q4	$20K	Buy	8,000 +3,030	+61%	+$7.09K	0.01%	211
2021 Q3	$13K	Hold	4,970	–	–	0.01%	249
2021 Q2	$14K	Hold	4,970	–	–	0.01%	238
2021 Q1	$12K	Hold	4,970	–	–	0.01%	232
2020 Q4	$9K	Buy	+4,970	New	+$6.95K	0.01%	254
2020 Q1	$4K	Hold	4,970	–	–	﹤0.01%	277
2019 Q4	$4K	Hold	4,970	–	–	﹤0.01%	300
2019 Q3	$5K	Hold	4,970	–	–	﹤0.01%	291
2019 Q2	$5K	Hold	4,970	–	–	﹤0.01%	297
2019 Q1	$7K	Buy	+4,970	New	+$6.18K	0.01%	281

Other funds holding LCTX

Defender Capital Charlotte, North Carolina $319M AUM 12.55% 1-Year Est. Return

Hofer & Associates Thousand Oaks, California $143M AUM 11.29% 1-Year Est. Return

RCWM

Red Crane Wealth Management San Francisco, California $143M AUM 13.63% 1-Year Est. Return

CWM

Connecticut Wealth Management Farmington, Connecticut $2.73B AUM 14.39% 1-Year Est. Return

Chapin Davis Baltimore, Maryland $520M AUM 117.57% 1-Year Est. Return

Anchyra Partners Atlanta, Georgia $477M AUM 34.33% 1-Year Est. Return

ELCO Management New York $213M AUM 25.23% 1-Year Est. Return

Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Founders Capital Management (Texas)'s LCTX Position: Q3 2026 in Review

Founders Capital Management (Texas) held its Lineage Cell Therapeutics (LCTX) position steady in Q3 2026 at 16,000 shares worth $15.3K. The position accounts for 0.01% of the portfolio, ranked #67.

Founders Capital Management (Texas) first reported a position in LCTX in Q1 2019 and has held it in 28 quarters since. The position peaked at $25.3K in Q1 2026. 11 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

Founders Capital Management (Texas) held 16,000 shares of Lineage Cell Therapeutics worth $15.3K as of Q3 2026.
Founders Capital Management (Texas) left its Lineage Cell Therapeutics share count unchanged in Q3 2026.
Lineage Cell Therapeutics made up 0.01% of Founders Capital Management (Texas)'s portfolio in Q3 2026, its #67 holding.
Founders Capital Management (Texas) first reported a position in Lineage Cell Therapeutics in Q1 2019 and has held it in 28 quarters since.
Founders Capital Management (Texas)'s Lineage Cell Therapeutics position peaked at $25.3K in Q1 2026.
11 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Founders Capital Management (Texas)'s 13F filing for Q3 2026, filed 13 Oct 2026.